April 27-29, 2026
The Ritz-Carlton, Tysons Corner | McLean, VAKey Sessions
Lisa LeCointe-Cephas
Chairperson's Opening Remarks
Johnson & Johnson Innovative Medicine
Jill Fallows Macaluso
FIRESIDE KEYNOTE When a Culture of Compliance Becomes a Competitive Advantage
Novo Nordisk
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
2026 Day 2 Agenda - ET (Eastern Time, GMT-05:00)
keyboard_arrow_leftSearch & Filter
close
Streams
Formats
2026 Day 2 Agenda - ET (Eastern Time, GMT-05:00)
close
Streams
Formats
Showing 1 of 1 Streams
Main Stage
11:20am - 12:00pm
Former Prosecutors Panel - Interpreting the Latest DOJ Actions and Investigations
- Commentary on the latest developments from DOJ
- Update on DOJ’s health care fraud, FCPA, and other corporate enforcement
- DOJ guidance to prosecutors and its significance for pharmaceutical companies
- The current state of False Claims Act litigation
- Amanda Masselam Strachan - Partner, Wilmer Hale
- Lee Cortes - Partner, Arnold & Porter
- Diane Seol - Of Counsel, Choate
Topic Intensives - Delve into the detail with practical scenarios and hands on approaches
Showing 1 of 1 Streams
Topic Intensive A
3:50pm - 4:45pm
Guardrails for Evolving Field Facing Roles
- How can we ensure we are communicating in every way we can communicate whilst remaining compliant?
- Interactions with GPOs – examining the types of interactions with field roles, what they can talk about and what can they do
- Medical commercial interactions: helping Compliance keep pace with agile approaches
- Considerations when using scientific platforms to engage HCPs
- Kimberly Gregorio - Vice President, Commercial Excellence and Client Engagement, P360
- Peter Agnoletto - Ethics and Business Integrity Global Head for aT1D&CVM Franchise and US General Medicines Strategic Advisor, Sanofi
- Alicia Whittlesey - Partner, Porzio, Bromberg, & Newman
Filter
Streams
Formats